Valuation: Evolus, Inc.

Market Cap 485M 433M 398M 362M 678M 45.96B 692M 4.75B 1.91B 24.26B 1.82B 1.78B 76.62B P/E 2026 *
-14.9x
P/E 2027 * -47.1x
Enterprise Value 606M 541M 497M 452M 847M 57.41B 864M 5.93B 2.39B 30.3B 2.28B 2.23B 95.72B EV / Sales 2026 *
1.81x
EV / Sales 2027 * 1.56x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -
1 day-2.59%
1 week-0.14%
Current month-2.59%
1 month+0.28%
3 months+18.35%
6 months+28.32%
Current year+7.67%
1 week 7.07
Extreme 7.07
7.83
1 month 6.9
Extreme 6.9
7.83
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 05/05/2018
Director of Finance/CFO 48 07/09/2025
Chief Operating Officer - 31/08/2022
Director TitleAgeSince
Chairman 63 31/12/2017
Director/Board Member 71 11/02/2018
Director/Board Member 48 05/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Chief Executive Officer

-105,108 0.1625%
20/03/26 Sell

Chief Executive Officer

13,669 0.0211%
20/03/26 Sell

Chief Technology Officer

3,119 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-0.14%+12.05%-7.97% 485M
-0.46%+10.31%+57.38%+143.15% 1,263B
-0.97%+1.60%+45.26%+80.09% 658B
-2.05%+0.73%+36.27%+101.62% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.78%+5.51%+79.85%+44.25% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
-0.12%+4.68%+57.09%+74.59% 252B
-0.21%+7.34%+39.56%+109.69% 212B
Average -0.98%+5.79%+42.48%+70.13% 426.24B
Weighted average by Cap. -0.79%+6.60%+48.68%+93.28%

Financials

2026 *2027 *
Net sales 334M 298M 274M 249M 467M 31.63B 476M 3.27B 1.32B 16.7B 1.25B 1.23B 52.74B 392M 350M 321M 292M 548M 37.13B 559M 3.84B 1.55B 19.6B 1.47B 1.44B 61.9B
Net income -31.58M -28.19M -25.87M -23.53M -44.12M -2.99B -45M -309M -125M -1.58B -119M -116M -4.98B -9.05M -8.08M -7.41M -6.74M -12.64M -857M -12.89M -88.54M -35.69M -452M -33.96M -33.23M -1.43B
Net Debt 121M 108M 99.13M 90.18M 169M 11.46B 172M 1.18B 477M 6.05B 454M 444M 19.1B 126M 112M 103M 93.9M 176M 11.93B 180M 1.23B 497M 6.3B 473M 463M 19.89B
Projected Income Statement - Annual - Evolus, Inc.
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
02/11/26 US$7.160 -2.59% 712,590
30/10/26 US$7.350 -2.26% 794,425
29/10/26 US$7.520 -1.51% 789,231
28/10/26 US$7.635 +3.60% 671,397
27/10/26 US$7.370 +2.79% 602,099
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Evolus, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.350USD
Average target price
15.00USD
Spread / Average Target
+104.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evolus, Inc.
  1. Stock Market
  2. Stocks
  3. EOLS Stock